WHO Study: Remdesivir does not help hospitalised COVID-19 patients

According to a study by the World Health Organisation (WHO) has found that Remdesivir does not help hospitalised COVID-19 patients. The study titled Repurposed antiviral drugs for COVID-19–interim WHO SOLIDARITY trial results found that Remdesivir, Hydroxychloroquine, Lopinavir and Interferon regimens appeared to have little or no effect on hospitalized COVID-19, as indicated by overall mortality, initiation of ventilation and duration of hospital stay. 

“The big story is the finding that remdesivir produces no meaningful impact on survival,” Martin Landray, an Oxford University professor who led other coronavirus treatment research, said in a statement. 

“This is a drug that has to be given by intravenous infusion for five to 10 days,” and costs about $2,550 per treatment course, he said. “COVID affects millions of people and their families around the world. We need scalable, affordable and equitable treatments. 

Photo Credit : https://www.flickr.com/photos/91261194@N06/49882602878 

Comments are closed, but trackbacks and pingbacks are open.